Advertisement

Psychopharmacology

, Volume 235, Issue 6, pp 1759–1773 | Cite as

New steps for treating alcohol use disorder

  • Erin J. Campbell
  • Andrew J. Lawrence
  • Christina J. Perry
Review

Abstract

Alcohol use disorder is a complex syndrome with multiple treatment points including drug-induced pathology, withdrawal management, behavioral/cognitive strategies, and relapse prevention. These different components may be complicated by genotype and phenotype. A huge milestone for the treatment of alcohol use disorder across several countries in the last 10 years was the introduction of practice guidelines integrating clinical expertise and research evidence. These provide a summary of interventions that have been shown to be effective following rigorous and replicated clinical trials. Inspection of these guidelines reveals good consistency, but little evidence of progress in treatment approaches for alcohol use disorder over the past decade. In this mini-review, we discuss emerging treatments for alcohol use disorder that may supplement or improve the evidence-based treatments that are currently recommended. New medications, the emergence of digital technology, and other novel approaches such as transcranial magnetic stimulation are all discussed with reference to treatments already in practice. We also consider how individual differences in genotype and phenotype may affect outcomes. Together with improvements in technology, this knowledge offers a powerful tool for designing personalized approaches to treatment, and hence improving prognosis for rehabilitation programs.

Keywords

Alcohol use disorder Therapy Drug repositioning Precision medicine Transcranial magnetic stimulation 

Notes

Funding

This work was supported by a National Health and Medical Research Council Project Grant (AJL, 1105741), a National Health and Medical Research Council Principal Research Fellowship (AJL, 1116930), a National Health and Medical Research Council/Australian Research Council Fellowship (CJP, 1107144), and the Victorian State Government Operational Infrastructure Scheme.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflicts of interest.

References

  1. Addolorato G, Caputo F, Capristo E, Colombo G, Gessa GL, Gasbarrini G (2000) Ability of baclofen in reducing alcohol craving and intake: II—preliminary clinical evidence. Alcohol Clin Exp Res 24(1):67–71PubMedGoogle Scholar
  2. Addolorato G, Caputo F, Capristo E, Domenicali M, Bernardi M, Janiri L, Agabio R, Colombo G, Gessa GL, Gasbarrini G (2002a) Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study. Alcohol Alcohol 37(5):504–508PubMedCrossRefGoogle Scholar
  3. Addolorato G, Caputo F, Capristo E, Janiri L, Bernardi M, Agabio R, Colombo G, Gessa GL, Gasbarrini G (2002b) Rapid suppression of alcohol withdrawal syndrome by baclofen. Am J Med 112(3):226–229PubMedCrossRefGoogle Scholar
  4. Addolorato G, Antonelli M, Cocciolillo F, Vassallo GA, Tarli C, Sestito L, Mirijello A, Ferrulli A, Pizzuto DA, Camardese G, Miceli A, Diana M, Giordaon A, Gasbarrini A, Di Giuda D (2017) Deep transcranial magnetic stimulation of the dorsolateral prefrontal cortex in alcohol use disorder patients: effects on dopamine transporter availability and alcohol intake. Eur Neuropsychopharmacol 27(5):450–461.  https://doi.org/10.1016/j.euroneuro.2017.03.008 PubMedCrossRefGoogle Scholar
  5. Agabio R, Colombo G (2014) GABAB receptor ligands for the treatment of alcohol use disorder: preclinical and clinical evidence. Front Neurosci 8:140.  https://doi.org/10.3389/fnins.2014.00140 PubMedPubMedCentralCrossRefGoogle Scholar
  6. Alba-Ferrara L, Fernandez F, Salas R, de Erausquin GA (2014) Transcranial magnetic stimulation and deep brain stimulation in the treatment of alcohol dependence. Addict Disord Their Treat 13(4):159–169.  https://doi.org/10.1097/ADT.0b013e31829cf047 PubMedPubMedCentralCrossRefGoogle Scholar
  7. Ameisen O (2005) Complete and prolonged suppression of symptoms and consequences of alcohol-dependence using high-dose baclofen: a self-case report of a physician. Alcohol Alcohol 40(2):147–150.  https://doi.org/10.1093/alcalc/agh130 PubMedCrossRefGoogle Scholar
  8. American Psychiatric Association (2006) Practice guideline for the treatment of patients with substance use disorders. American Psychiatric AssociationGoogle Scholar
  9. American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders, 5th edn. American Psychiatric Association, ArlingtonCrossRefGoogle Scholar
  10. Anton RF, O'Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, Combine Study Research Group (2006) Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 295(17):2003–2017.  https://doi.org/10.1001/jama.295.17.2003 PubMedCrossRefGoogle Scholar
  11. Apollonio D, Philipps R, Bero L (2016) Interventions for tobacco use cessation in people in treatment for or recovery from substance use disorders. Cochrane Database Syst Rev 11:CD010274.  https://doi.org/10.1002/14651858.CD010274.pub2 PubMedCrossRefGoogle Scholar
  12. Arias AJ, Feinn R, Oncken C, Covault J, Kranzler HR (2010) Placebo-controlled trial of zonisamide for the treatment of alcohol dependence. J Clin Psychopharmacol 30(3):318–322.  https://doi.org/10.1097/JCP.0b013e3181db38bb PubMedPubMedCentralCrossRefGoogle Scholar
  13. Ashburn TT, Thor KB (2004) Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 3(8):673–683.  https://doi.org/10.1038/nrd1468 PubMedCrossRefGoogle Scholar
  14. Australian Government Department of Health and Ageing (2009) Guidelines for the treatment of alcohol problems. Commonwealth of Australia, SydneyGoogle Scholar
  15. Balhara Y, Verma R (2014) A review of web based interventions focusing on alcohol use. Ann Med Health Sci Res 4(4):472–480.  https://doi.org/10.4103/2141-9248.139272 PubMedPubMedCentralCrossRefGoogle Scholar
  16. Bates ME, Bowden SC, Barry D (2002) Neurocognitive impairment associated with alcohol use disorders: implications for treatment. Exp Clin Psychopharmacol 10(3):193–212.  https://doi.org/10.1037/1064-1297.10.3.193 PubMedCrossRefGoogle Scholar
  17. Bates ME, Pawlak AP, Tonigan JS, Buckman JF (2006) Cognitive impairment influences drinking outcome by altering therapeutic mechanisms of change. Psychol Addict Behav 20(3):241–253.  https://doi.org/10.1037/0893-164X.20.3.241 PubMedPubMedCentralCrossRefGoogle Scholar
  18. Bates ME, Buckman JF, Nguyen TT (2013) A role for cognitive rehabilitation in increasing the effectiveness of treatment for alcohol use disorders. Neuropsychol Rev 23(1):27–47.  https://doi.org/10.1007/s11065-013-9228-3 PubMedPubMedCentralCrossRefGoogle Scholar
  19. Batki SL, Pennington DL (2014) Toward personalized medicine in the pharmacotherapy of alcohol use disorder: targeting patient genes and patient goals. Am J Psychiatry 171(4):391–394.  https://doi.org/10.1176/appi.ajp.2014.14010061 PubMedCrossRefGoogle Scholar
  20. Biton V (2007) Clinical pharmacology and mechanism of action of zonisamide. Clin Neuropharmacol 30(4):230–240.  https://doi.org/10.1097/wnf.0b013e3180413d7d PubMedCrossRefGoogle Scholar
  21. Blaine SK, Sinha R (2017) Alcohol, stress, and glucocorticoids: from risk to dependence and relapse in alcohol use disorders. Neuropharmacology 122:136–147.  https://doi.org/10.1016/j.neuropharm.2017.01.037 PubMedCrossRefPubMedCentralGoogle Scholar
  22. Blaine SK, Milivojevic V, Fox H, Sinha R (2016) Alcohol effects on stress pathways: impact on craving and relapse risk. Can J Psychiatr 61(3):145–153.  https://doi.org/10.1177/0706743716632512 CrossRefGoogle Scholar
  23. Blankers M, Koeter MW, Schippers GM (2011) Internet therapy versus internet self-help versus no treatment for problematic alcohol use: a randomized controlled trial. J Consult Clin Psychol 79(3):330–341.  https://doi.org/10.1037/a0023498 PubMedCrossRefGoogle Scholar
  24. Boggio PS, Sultani N, Fecteau S, Merabet L, Mecca T, Pascual-Leone A, Basaglia A, Fregni F (2008) Prefrontal cortex modulation using transcranial DC stimulation reduces alcohol craving: a double-blind, sham-controlled study. Drug Alcohol Depend 92(1–3):55–60.  https://doi.org/10.1016/j.drugalcdep.2007.06.011 PubMedCrossRefGoogle Scholar
  25. Breese GR, Sinha R, Heilig M (2011) Chronic alcohol neuroadaptation and stress contribute to susceptibility for alcohol craving and relapse. Pharmacol Ther 129(2):149–171.  https://doi.org/10.1016/j.pharmthera.2010.09.007 PubMedCrossRefGoogle Scholar
  26. Bucknam W (2007) Suppression of symptoms of alcohol dependence and craving using high-dose baclofen. Alcohol Alcohol 42(2):158–160.  https://doi.org/10.1093/alcalc/agl091 PubMedCrossRefGoogle Scholar
  27. Cahill K, Lindson-Hawley N, Thomas KH, Fanshawe TR, Lancaster T (2016) Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 5:CD006103.  https://doi.org/10.1002/14651858.CD006103.pub7 CrossRefGoogle Scholar
  28. Caldwell LC, Schweinsburg AD, Nagel BJ, Barlett VC, Brown SA, Tapert SF (2005) Gender and adolescent alcohol use disorders on BOLD (blood oxygen level dependent) response to spatial working memory. Alcohol Alcohol 40(3):194–200.  https://doi.org/10.1093/alcalc/agh134 PubMedPubMedCentralCrossRefGoogle Scholar
  29. Campbell AN, Nunes EV, Matthews AG, Stitzer M, Miele GM, Polsky D, Turrigiano E, Walters S, McClure EA, Kyle TL, Wahle A, Van Veldhuisen P, Goldman B, Babcock D, Stabile PQ, Winhusen T, Ghitza UE (2014) Internet-delivered treatment for substance abuse: a multisite randomized controlled trial. Am J Psychiatry 171(6):683–690.  https://doi.org/10.1176/appi.ajp.2014.13081055 PubMedPubMedCentralCrossRefGoogle Scholar
  30. Caputo F, Vignoli T, Tarli C, Domenicali M, Zoli G, Bernardi M, Addolorato G (2016) A brief up-date of the use of sodium oxybate for the treatment of alcohol use disorder. Int J Environ Res Public Health 13(3):290.  https://doi.org/10.3390/ijerph13030290 PubMedCentralCrossRefGoogle Scholar
  31. Carey KB, Scott-Sheldon LA, Carey MP, DeMartini KS (2007) Individual-level interventions to reduce college student drinking: a meta-analytic review. Addict Behav 32(11):2469–2494.  https://doi.org/10.1016/j.addbeh.2007.05.004 PubMedPubMedCentralCrossRefGoogle Scholar
  32. Carey KB, Scott-Sheldon LA, Garey L, Elliott JC, Carey MP (2016) Alcohol interventions for mandated college students: a meta-analytic review. J Consult Clin Psychol 84(7):619–632.  https://doi.org/10.1037/a0040275 PubMedPubMedCentralCrossRefGoogle Scholar
  33. Carroll KM, Kiluk BD (2017) Cognitive behavioral interventions for alcohol and drug use disorders: through the stage model and back again. Psychol Addict Behav.  https://doi.org/10.1037/adb0000311
  34. Carroll KM, Onken LS (2005) Behavioral therapies for drug abuse. Am J Psychiatry 162(8):1452–1460.  https://doi.org/10.1176/appi.ajp.162.8.1452 PubMedPubMedCentralCrossRefGoogle Scholar
  35. Ceccanti M, Inghilleri M, Attilia ML, Raccah R, Fiore M, Zangen A, Ceccanti M (2015) Deep TMS on alcoholics: effects on cortisolemia and dopamine pathway modulation. A pilot study. Can J Physiol Pharmacol 93(4):283–290.  https://doi.org/10.1139/cjpp-2014-0188 PubMedCrossRefGoogle Scholar
  36. Cohn AM, Hunter-Reel D, Hagman BT, Mitchell J (2011) Promoting behavior change from alcohol use through mobile technology: the future of ecological momentary assessment. Alcohol Clin Exp Res 35(12):2209–2215.  https://doi.org/10.1111/j.1530-0277.2011.01571.x PubMedPubMedCentralCrossRefGoogle Scholar
  37. Collins FS, Varmus H (2015) A new initiative on precision medicine. N Engl J Med 372(9):793–795.  https://doi.org/10.1056/NEJMp1500523 PubMedPubMedCentralCrossRefGoogle Scholar
  38. Conklin CA, Tiffany ST (2002) Applying extinction research and theory to cue-exposure addiction treatments. Addiction 97(2):155–167PubMedCrossRefGoogle Scholar
  39. Conway KP, Swendsen J, Husky MM, He JP, Merikangas KR (2016) Association of Lifetime Mental Disorders and Subsequent Alcohol and Illicit Drug Use: results from the National Comorbidity Survey-Adolescent Supplement. J Am Acad Child Adolesc Psychiatry 55(4):280–288.  https://doi.org/10.1016/j.jaac.2016.01.006 PubMedCrossRefGoogle Scholar
  40. Cristea IA, Kok RN, Cuijpers P (2016) The effectiveness of cognitive bias modification interventions for substance addictions: a meta-analysis. PLoS One 11(9):e0162226.  https://doi.org/10.1371/journal.pone.0162226 PubMedPubMedCentralCrossRefGoogle Scholar
  41. da Silva MC, Conti CL, Klauss J, Alves LG, do Nascimento Cavalcante HM, Fregni F, Nakamura-Palacios EM (2013) Behavioral effects of transcranial direct current stimulation (tDCS) induced dorsolateral prefrontal cortex plasticity in alcohol dependence. J Physiol Paris 107(6):493–502.  https://doi.org/10.1016/j.jphysparis.2013.07.003 PubMedCrossRefGoogle Scholar
  42. den Uyl TE, Gladwin TE, Wiers RW (2015) Transcranial direct current stimulation, implicit alcohol associations and craving. Biol Psychol 105:37–42.  https://doi.org/10.1016/j.biopsycho.2014.12.004 CrossRefGoogle Scholar
  43. Dario A, Tomei G (2004) A benefit-risk assessment of baclofen in severe spinal spasticity. Drug Saf 27(11):799–818PubMedCrossRefGoogle Scholar
  44. Dougherty DM, Lake SL, Hill-Kapturczak N, Liang Y, Karns TE, Mullen J, Roache JD (2015) Using contingency management procedures to reduce at-risk drinking in heavy drinkers. Alcohol Clin Exp Res 39(4):743–751.  https://doi.org/10.1111/acer.12687 PubMedPubMedCentralCrossRefGoogle Scholar
  45. Dulin PL, Gonzalez VM (2017) Smartphone-based, momentary intervention for alcohol cravings amongst individuals with an alcohol use disorder. Psychol Addict Behav 31(5):601–607.  https://doi.org/10.1037/adb0000292 PubMedCrossRefPubMedCentralGoogle Scholar
  46. Farris SP, Arasappan D, Hunicke-Smith S, Harris RA, Mayfield RD (2015) Transcriptome organization for chronic alcohol abuse in human brain. Mol Psychiatry 20(11):1438–1447.  https://doi.org/10.1038/mp.2014.159 PubMedCrossRefGoogle Scholar
  47. Feeney GF, Young RM, Connor JP, Tucker J, McPherson A (2002) Cognitive behavioural therapy combined with the relapse-prevention medication acamprosate: are short-term treatment outcomes for alcohol dependence improved? Aust N Z J Psychiatry 36(5):622–628PubMedCrossRefGoogle Scholar
  48. Fernandez AC, Yurasek AM, Merrill JE, Miller MB, Zamboanga BL, Carey KB, Borsari B (2017) Do brief motivational interventions reduce drinking game frequency in mandated students? An analysis of data from two randomized controlled trials. Psychol Addict Behav 31(1):36–45.  https://doi.org/10.1037/adb0000239 PubMedCrossRefGoogle Scholar
  49. Ferrer-Garcia M, Gutierrez-Maldonado J, Pla J (2013) Cue-elicited anxiety and craving for food using virtual reality scenarios. Stud Health Technol Inform 191:105–109PubMedGoogle Scholar
  50. Fitzsimons H, Tuten M, Borsuk C, Lookatch S, Hanks L (2015) Clinician-delivered contingency management increases engagement and attendance in drug and alcohol treatment. Drug Alcohol Depend 152:62–67.  https://doi.org/10.1016/j.drugalcdep.2015.04.021 PubMedCrossRefGoogle Scholar
  51. Florez G, Saiz PA, Garcia-Portilla P, Alvarez S, Nogueiras L, Bobes J (2011) Topiramate for the treatment of alcohol dependence: comparison with naltrexone. Eur Addict Res 17(1):29–36.  https://doi.org/10.1159/000320471 PubMedCrossRefGoogle Scholar
  52. Fowler LA, Holt SL, Joshi D (2016) Mobile technology-based interventions for adult users of alcohol: a systematic review of the literature. Addict Behav 62:25–34.  https://doi.org/10.1016/j.addbeh.2016.06.008 PubMedCrossRefGoogle Scholar
  53. Foxcroft DR, Coombes L, Wood S, Allen D, Almeida Santimano NM, Moreira MT (2016) Motivational interviewing for the prevention of alcohol misuse in young adults. Cochrane Database Syst Rev 7:CD007025.  https://doi.org/10.1002/14651858.CD007025.pub4 PubMedCrossRefGoogle Scholar
  54. Frias J, Rodriguez R, Torres JM, Ruiz E, Ortega E (2000) Effects of acute alcohol intoxication on pituitary-gonadal axis hormones, pituitary-adrenal axis hormones, beta-endorphin and prolactin in human adolescents of both sexes. Life Sci 67(9):1081–1086PubMedCrossRefGoogle Scholar
  55. Furieri FA, Nakamura-Palacios EM (2007) Gabapentin reduces alcohol consumption and craving: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 68(11):1691–1700PubMedCrossRefGoogle Scholar
  56. Gastpar M, Bonnet U, Boning J, Mann K, Schmidt LG, Soyka M et al (2002) Lack of efficacy of naltrexone in the prevention of alcohol relapse: results from a German multicenter study. J Clin Psychopharmacol 22(6):592–598PubMedCrossRefGoogle Scholar
  57. Gimeno C, Dorado ML, Roncero C, Szerman N, Vega P, Balanza-Martinez V, Alvarez FJ (2017) Treatment of comorbid alcohol dependence and anxiety disorder: review of the scientific evidence and recommendations for treatment. Front Psychiatry 8:173.  https://doi.org/10.3389/fpsyt.2017.00173 PubMedPubMedCentralCrossRefGoogle Scholar
  58. Gladwin TE, Wiers CE, Wiers RW (2016) Cognitive neuroscience of cognitive retraining for addiction medicine: From mediating mechanisms to questions of efficacy. Prog Brain Res 224:323–344.  https://doi.org/10.1016/bs.pbr.2015.07.021 PubMedCrossRefGoogle Scholar
  59. Glasner-Edwards S, Rawson R (2010) Evidence-based practices in addiction treatment: review and recommendations for public policy. Health Policy 97(2–3):93–104.  https://doi.org/10.1016/j.healthpol.2010.05.013 PubMedPubMedCentralCrossRefGoogle Scholar
  60. Gonzalez VM, Dulin PL (2015) Comparison of a smartphone app for alcohol use disorders with an internet-based intervention plus bibliotherapy: a pilot study. J Consult Clin Psychol 83(2):335–345.  https://doi.org/10.1037/a0038620 PubMedPubMedCentralCrossRefGoogle Scholar
  61. Grant BF, Goldstein RB, Saha TD, Chou SP, Jung J, Zhang H, Pickering RP, Ruan WJ, Smith SM, Huang B, Hasin DS (2015) Epidemiology of DSM-5 alcohol use disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions III. JAMA Psychiatry 72(8):757–766.  https://doi.org/10.1001/jamapsychiatry.2015.0584 PubMedPubMedCentralCrossRefGoogle Scholar
  62. Gustafson DH, McTavish FM, Chih MY, Atwood AK, Johnson RA, Boyle MG, Levy MS, Driscoll H, Chisholm SM, Dillenburg L, Isham A, Shah D (2014) A smartphone application to support recovery from alcoholism: a randomized clinical trial. JAMA Psychiatry 71(5):566–572.  https://doi.org/10.1001/jamapsychiatry.2013.4642 PubMedPubMedCentralCrossRefGoogle Scholar
  63. Hammarberg A, Jayaram-Lindstrom N, Beck O, Franck J, Reid MS (2009) The effects of acamprosate on alcohol-cue reactivity and alcohol priming in dependent patients: a randomized controlled trial. Psychopharmacology 205(1):53–62.  https://doi.org/10.1007/s00213-009-1515-6 PubMedCrossRefGoogle Scholar
  64. Hoeppner BB, Schick MR, Kelly LM, Hoeppner SS, Bergman B, Kelly JF (2017) There is an app for that—or is there? A content analysis of publicly available smartphone apps for managing alcohol use. J Subst Abus Treat 82:67–73.  https://doi.org/10.1016/j.jsat.2017.09.006 CrossRefGoogle Scholar
  65. Houben K, Wiers RW, Jansen A (2011) Getting a grip on drinking behavior: training working memory to reduce alcohol abuse. Psychol Sci 22(7):968–975.  https://doi.org/10.1177/0956797611412392 PubMedCrossRefGoogle Scholar
  66. Ipser JC, Wilson D, Akindipe TO, Sager C, Stein DJ (2015) Pharmacotherapy for anxiety and comorbid alcohol use disorders. Cochrane Database Syst Rev 1:CD007505.  https://doi.org/10.1002/14651858.CD007505.pub2 PubMedCrossRefGoogle Scholar
  67. Jain KK (2010) Innovative diagnostic technologies and their significance for personalized medicine. Mol Diagn Ther 14(3):141–147.  https://doi.org/10.2165/11536240-000000000-00000 PubMedCrossRefGoogle Scholar
  68. Jain KK (2017) Personalized management of cardiovascular disorders. Med Princ Pract 26(5):399–414.  https://doi.org/10.1159/000481403 PubMedPubMedCentralCrossRefGoogle Scholar
  69. Jiang S, Wu L, Gao X (2017) Beyond face-to-face individual counseling: a systematic review on alternative modes of motivational interviewing in substance abuse treatment and prevention. Addict Behav 73:216–235.  https://doi.org/10.1016/j.addbeh.2017.05.023 PubMedCrossRefGoogle Scholar
  70. Johnson BA, Ait-Daoud N, Bowden CL, DiClemente CC, Roache JD, Lawson K, Javors MA, Ma JZ (2003) Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet 361(9370):1677–1685.  https://doi.org/10.1016/s0140-6736(03)13370-3 PubMedCrossRefGoogle Scholar
  71. Johnson BA, Ait-Daoud N, Akhtar FZ, Ma JZ (2004) Oral topiramate reduces the consequences of drinking and improves thequality of life of alcohol-dependent individuals: a randomized controlled trial. Arch Gen Psychiatry 61(9):905–912.  https://doi.org/10.1001/archpsyc.61.9.905 PubMedCrossRefGoogle Scholar
  72. Johnson BA, Rosenthal N, Capece JA, Wiegand F, Mao L, Beyers K, McKay A, Ait-Daoud N, Anton RF, Ciraulo DA, Kranzler HR, Mann K, O'Malley SS, Swift RM (2007) Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA 298(14):1641–1651.  https://doi.org/10.1001/jama.298.14.1641 PubMedCrossRefGoogle Scholar
  73. Johnson BA, Ait-Daoud N, Seneviratne C, Roache JD, Javors MA, Wang XQ, Liu L, Penberthy JK, DiClemente CC, Li MD (2011) Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking. Am J Psychiatry 168(3):265–275.  https://doi.org/10.1176/appi.ajp.2010.10050755 PubMedPubMedCentralCrossRefGoogle Scholar
  74. Karpyak VM, Biernacka JM, Geske JR, Jenkins GD, Cunningham JM, Ruegg J et al (2014) Genetic markers associated with abstinence length in alcohol-dependent subjects treated with acamprosate. Transl Psychiatry 4:e462.  https://doi.org/10.1038/tp.2014.103 PubMedCrossRefGoogle Scholar
  75. Kaskutas LA (2009) Alcoholics anonymous effectiveness: faith meets science. J Addict Dis 28(2):145–157.  https://doi.org/10.1080/10550880902772464 PubMedPubMedCentralCrossRefGoogle Scholar
  76. Kaskutas LA, Bond J, Avalos LA (2009) 7-year trajectories of Alcoholics Anonymous attendance and associations with treatment. Addict Behav 34(12):1029–1035.  https://doi.org/10.1016/j.addbeh.2009.06.015 PubMedPubMedCentralCrossRefGoogle Scholar
  77. Kay-Lambkin FJ, Baker AL, Lewin TJ, Carr VJ (2009) Computer-based psychological treatment for comorbid depression and problematic alcohol and/or cannabis use: a randomized controlled trial of clinical efficacy. Addiction 104(3):378–388.  https://doi.org/10.1111/j.1360-0443.2008.02444.x PubMedCrossRefGoogle Scholar
  78. Kelly JF, Yeterian JD, Cristello JV, Kaminer Y, Kahler CW, Timko C (2016) Developing and testing twelve-step facilitation for adolescents with substance use disorder: manual development and preliminary outcomes. Subst Abus 10:55–64.  https://doi.org/10.4137/SART.S39635 CrossRefGoogle Scholar
  79. Khadjesari Z, Murray E, Hewitt C, Hartley S, Godfrey C (2011) Can stand-alone computer-based interventions reduce alcohol consumption? A systematic review. Addiction 106(2):267–282.  https://doi.org/10.1111/j.1360-0443.2010.03214.x PubMedCrossRefGoogle Scholar
  80. Khan A, Levy P, DeHorn S, Miller W, Compton S (2008) Predictors of mortality in patients with delirium tremens. Acad Emerg Med 15(8):788–790.  https://doi.org/10.1111/j.1553-2712.2008.00187.x PubMedCrossRefGoogle Scholar
  81. Knapp CM, Sarid-Segal O, Richardson MA, Colaneri LS, Afshar M, Devine E et al (2010) Open label trial of the tolerability and efficacy of zonisamide in the treatment of alcohol dependence. Am J Drug Alcohol Abuse 36(2):102–105.  https://doi.org/10.3109/00952991003674812 PubMedPubMedCentralCrossRefGoogle Scholar
  82. Knapp CM, Ciraulo DA, Sarid-Segal O, Richardson MA, Devine E, Streeter CC et al (2015) Zonisamide, topiramate, and levetiracetam: efficacy and neuropsychological effects in alcohol use disorders. J Clin Psychopharmacol 35(1):34–42.  https://doi.org/10.1097/jcp.0000000000000246 PubMedCrossRefGoogle Scholar
  83. Krampe H, Ehrenreich H (2010) Supervised disulfiram as adjunct to psychotherapy in alcoholism treatment. Curr Pharm Des 16(19):2076–2090PubMedCrossRefGoogle Scholar
  84. Kranzler HR, Pierucci-Lagha A, Feinn R, Hernandez-Avila C (2003) Effects of ondansetron in early- versus late-onset alcoholics: a prospective, open-label study. Alcohol Clin Exp Res 27(7):1150–1155.  https://doi.org/10.1097/01.ALC.0000075547.77464.76 PubMedCrossRefGoogle Scholar
  85. Kranzler HR, Smith RV, Schnoll R, Moustafa A, Greenstreet-Akman E (2017) Precision medicine and pharmacogenetics: what does oncology have that addiction medicine does not?. Addiction 112(12):2086–2094PubMedCrossRefGoogle Scholar
  86. Krenek M, Maisto SA, Funderburk JS, Drayer R (2011) Severity of alcohol problems and readiness to change alcohol use in primary care. Addict Behav 36(5):512–515.  https://doi.org/10.1016/j.addbeh.2010.12.023 PubMedCrossRefGoogle Scholar
  87. Krystal JH, Cramer JA, Krol WF, Kirk GF, Rosenheck RA, Veterans Affairs Naltrexone Cooperative Study, G (2001) Naltrexone in the treatment of alcohol dependence. N Engl J Med 345(24):1734–1739.  https://doi.org/10.1056/NEJMoa011127 PubMedCrossRefGoogle Scholar
  88. Kuhn J, Grundler TO, Bauer R, Huff W, Fischer AG, Lenartz D et al (2011) Successful deep brain stimulation of the nucleus accumbens in severe alcohol dependence is associated with changed performance monitoring. Addict Biol 16(4):620–623.  https://doi.org/10.1111/j.1369-1600.2011.00337.x PubMedCrossRefGoogle Scholar
  89. Kushner MG, Sletten S, Donahue C, Thuras P, Maurer E, Schneider A et al (2009) Cognitive-behavioral therapy for panic disorder in patients being treated for alcohol dependence: moderating effects of alcohol outcome expectancies. Addict Behav 34(6–7):554–560.  https://doi.org/10.1016/j.addbeh.2009.03.011 PubMedPubMedCentralCrossRefGoogle Scholar
  90. Kutscher S, Heise DJ, Banger M, Saller B, Michel MC, Gastpar M et al (2002) Concomitant endocrine and immune alterations during alcohol intoxication and acute withdrawal in alcohol-dependent subjects. Neuropsychobiology 45(3):144–149.  https://doi.org/10.1159/000054955 PubMedCrossRefGoogle Scholar
  91. Le Berre AP, Vabret F, Cauvin C, Pinon K, Allain P, Pitel AL, Eustache F, Beaunieux H (2012) Cognitive barriers to readiness to change in alcohol-dependent patients. Alcohol Clin Exp Res 36(9):1542–1549.  https://doi.org/10.1111/j.1530-0277.2012.01760. PubMedCrossRefGoogle Scholar
  92. Lee JH, Kwon H, Choi J, Yang BH (2007) Cue-exposure therapy to decrease alcohol craving in virtual environment. Cyberpsychol Behav 10(5):617–623.  https://doi.org/10.1089/cpb.2007.9978 PubMedCrossRefGoogle Scholar
  93. Leggio L, Zywiak WH, Fricchione SR, Edwards SM, de la Monte SM, Swift RM, Kenna GA (2014) Intravenous ghrelin administration increases alcohol craving in alcohol-dependent heavy drinkers: a preliminary investigation. Biol Psychiatry 76(9):734–741.  https://doi.org/10.1016/j.biopsych.2014.03.019 PubMedPubMedCentralCrossRefGoogle Scholar
  94. Lemke S, Schutte KK, Brennan PL, Moos RH (2008) Gender differences in social influences and stressors linked to increased drinking. J Stud Alcohol Drugs 69(5):695–702PubMedPubMedCentralCrossRefGoogle Scholar
  95. Liang JH, Chen F, Krstew E, Cowen MS, Carroll FY, Crawford D et al (2006) The GABA(B) receptor allosteric modulator CGP7930, like baclofen, reduces operant self-administration of ethanol in alcohol-preferring rats. Neuropharmacology 50(5):632–639.  https://doi.org/10.1016/j.neuropharm.2005.11.011 PubMedCrossRefGoogle Scholar
  96. Liang J and Olsen RW (2014) Alcohol use disorders and current pharmacological therapies: the role of GABA(A) receptors. Acta Pharmacol Sin 35(8):981–93.  https://doi.org/10.1038/aps.2014.50 PubMedPubMedCentralCrossRefGoogle Scholar
  97. Lieberman DZ, Huang SW (2008) A technological approach to reaching a hidden population of problem drinkers. Psychiatr Serv 59(3):297–303.  https://doi.org/10.1176/appi.ps.59.3.2910.1176/ps.2008.59.3.297 PubMedCrossRefGoogle Scholar
  98. Loeber S, Croissant B, Heinz A, Mann K, Flor H (2006) Cue exposure in the treatment of alcohol dependence: effects on drinking outcome, craving and self-efficacy. Br J Clin Psychol 45(Pt 4):515–529.  https://doi.org/10.1348/014466505X82586 PubMedCrossRefGoogle Scholar
  99. Long D, Long B, Koyfman A (2017) The emergency medicine management of severe alcohol withdrawal. Am J Emerg Med 35(7):1005–1011.  https://doi.org/10.1016/j.ajem.2017.02.002 PubMedCrossRefGoogle Scholar
  100. Lyon J (2017) More treatments on deck for alcohol use disorder. JAMA 317(22):2267–2269.  https://doi.org/10.1001/jama.2017.4760 PubMedCrossRefGoogle Scholar
  101. Maccioni P, Zaru A, Loi B, Lobina C, Carai MA, Gessa GL et al (2012) Comparison of the effect of the GABABeta receptor agonist, baclofen, and the positive allosteric modulator of the GABAB receptor, GS39783, on alcohol self-administration in 3 different lines of alcohol-preferring rats. Alcohol Clin Exp Res 36(10):1748–1766.  https://doi.org/10.1111/j.1530-0277.2012.01782.x PubMedPubMedCentralCrossRefGoogle Scholar
  102. Maisel NC, Blodgett JC, Wilbourne PL, Humphreys K, Finney JW (2013) Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful? Addiction 108(2):275–293.  https://doi.org/10.1111/j.1360-0443.2012.04054.x PubMedCrossRefGoogle Scholar
  103. Majer JM, Jason LA, Ferrari JR, Miller SA (2011) 12-step involvement among a U.S. national sample of Oxford House residents. J Subst Abus Treat 41(1):37–44.  https://doi.org/10.1016/j.jsat.2011.01.010 CrossRefGoogle Scholar
  104. Mark TL, Kassed CA, Vandivort-Warren R, Levit KR, Kranzler HR (2009) Alcohol and opioid dependence medications: prescription trends, overall and by physician specialty. Drug Alcohol Depend 99(1–3):345–349.  https://doi.org/10.1016/j.drugalcdep.2008.07.018 PubMedCrossRefGoogle Scholar
  105. Martinotti G, di Nicola M, Frustaci A, Romanelli R, Tedeschi D, Guglielmo R et al (2010) Pregabalin, tiapride and lorazepam in alcohol withdrawal syndrome: a multi-centre, randomized, single-blind comparison trial. Addiction 105(2):288–299.  https://doi.org/10.1111/j.1360-0443.2009.02792.x PubMedCrossRefGoogle Scholar
  106. Mason BJ, Quello S, Goodell V, Shadan F, Kyle M, Begovic A (2014) Gabapentin treatment for alcohol dependence: a randomized clinical trial. JAMA Intern Med 174(1):70–77.  https://doi.org/10.1001/jamainternmed.2013.11950 PubMedPubMedCentralCrossRefGoogle Scholar
  107. Maurage P, Grynberg D, Noel X, Joassin F, Hanak C, Verbanck P et al (2011) The “reading the mind in the eyes” test as a new way to explore complex emotions decoding in alcohol dependence. Psychiatry Res 190(2–3):375–378.  https://doi.org/10.1016/j.psychres.2011.06.015 PubMedCrossRefGoogle Scholar
  108. McCaul ME, Wand GS, Stauffer R, Lee SM, Rohde CA (2001) Naltrexone dampens ethanol-induced cardiovascular and hypothalamic-pituitary-adrenal axis activation. Neuropsychopharmacology 25(4):537–547.  https://doi.org/10.1016/S0893-133X(01)00241-X PubMedCrossRefGoogle Scholar
  109. McDonell MG, Howell DN, McPherson S, Cameron JM, Srebnik D, Roll JM, Ries RK (2012) Voucher-based reinforcement for alcohol abstinence using the ethyl-glucuronide alcohol biomarker. J Appl Behav Anal 45(1):161–165.  https://doi.org/10.1901/jaba.2012.45-161 PubMedPubMedCentralCrossRefGoogle Scholar
  110. McGovern MP, Carroll KM (2003) Evidence-based practices for substance use disorders. Psychiatr Clin North Am 26(4):991–1010PubMedPubMedCentralCrossRefGoogle Scholar
  111. McQueen J, Howe TE, Allan L, Mains D, Hardy V (2011) Brief interventions for heavy alcohol users admitted to general hospital wards. Cochrane Database Syst Rev 8:CD005191.  https://doi.org/10.1002/14651858.CD005191.pub3 CrossRefGoogle Scholar
  112. Medina KL, McQueeny T, Nagel BJ, Hanson KL, Schweinsburg AD, Tapert SF (2008) Prefrontal cortex volumes in adolescents with alcohol use disorders: unique gender effects. Alcohol Clin Exp Res 32(3):386–394.  https://doi.org/10.1111/j.1530-0277.2007.00602.x PubMedPubMedCentralCrossRefGoogle Scholar
  113. Mellentin AI, Skot L, Nielsen B, Schippers GM, Nielsen AS, Stenager E, Juhl C (2017) Cue exposure therapy for the treatment of alcohol use disorders: a meta-analytic review. Clin Psychol Rev 57:195–207.  https://doi.org/10.1016/j.cpr.2017.07.006 PubMedCrossRefGoogle Scholar
  114. Miller WR, Rollnick S (2009) Ten things that motivational interviewing is not. Behav Cogn Psychother 37(2):129–140.  https://doi.org/10.1017/S1352465809005128 PubMedCrossRefGoogle Scholar
  115. Miller WR, Rollnick S (2014) The effectiveness and ineffectiveness of complex behavioral interventions: impact of treatment fidelity. Contemp Clin Trials 37(2):234–241.  https://doi.org/10.1016/j.cct.2014.01.005 PubMedCrossRefGoogle Scholar
  116. Miller WR, Rose GS (2009) Toward a theory of motivational interviewing. Am Psychol 64(6):527–537.  https://doi.org/10.1037/a0016830 PubMedPubMedCentralCrossRefGoogle Scholar
  117. Minozzi S, Amato L, Vecchi S, Davoli M (2010) Anticonvulsants for alcohol withdrawal. Cochrane Database Syst Rev 3:CD005064.  https://doi.org/10.1002/14651858.CD005064.pub3 CrossRefGoogle Scholar
  118. Minozzi, S., Saulle, R., & Rösner, S. (2017). Baclofen for alcohol use disorder. 2017(2), 1–15. doi: https://doi.org/10.1002/14651858.CD012557
  119. Mishra BR, Nizamie SH, Das B, Praharaj SK (2010) Efficacy of repetitive transcranial magnetic stimulation in alcohol dependence: a sham-controlled study. Addiction 105(1):49–55.  https://doi.org/10.1111/j.1360-0443.2009.02777.x PubMedCrossRefGoogle Scholar
  120. Mishra BR, Praharaj SK, Katshu MZ, Sarkar S, Nizamie SH (2015) Comparison of anticraving efficacy of right and left repetitive transcranial magnetic stimulation in alcohol dependence: a randomized double-blind study. J Neuropsychiatry Clin Neurosci 27(1):e54–e59.  https://doi.org/10.1176/appi.neuropsych.13010013 PubMedCrossRefGoogle Scholar
  121. Muench, F., van Stolk-Cooke, K., Kuerbis, A., Stadler, G., Baumel, A., Shao, S., ... Morgenstern, J. (2017). A randomized controlled pilot trial of different mobile messaging interventions for problem drinking compared to weekly drink tracking. PLoS One, 12(2), e0167900. doi: https://doi.org/10.1371/journal.pone.0167900
  122. Muller UJ, Sturm V, Voges J, Heinze HJ, Galazky I, Buntjen L et al (2016) Nucleus accumbens deep brain stimulation for alcohol addiction—safety and clinical long-term results of a pilot trial. Pharmacopsychiatry 49(4):170–173.  https://doi.org/10.1055/s-0042-104507 PubMedCrossRefGoogle Scholar
  123. Nakamura-Palacios, E. M., de Almeida Benevides, M. C., da Penha Zago-Gomes, M., de Oliveira, R. W., de Vasconcellos, V. F., de Castro, L. N., ... Fregni, F. (2012). Auditory event-related potentials (P3) and cognitive changes induced by frontal direct current stimulation in alcoholics according to Lesch alcoholism typology. Int J Neuropsychopharmacol, 15(5), 601–616. doi: https://doi.org/10.1017/S1461145711001040
  124. National Institute for Health and Care Excellence (2011) Alcohol-use disorders: diagnosis, assessment and management of harmful drinking and alcohol dependence. The British Psychological Society and The Royal College of Psychiatrists, LondonGoogle Scholar
  125. NIDA (2012) Principles of drug addiction treatment: a research-based guide (third edition)Google Scholar
  126. Office of the Surgeon General (2016) Reports of the surgeon general. In: Facing addiction in America: the surgeon general’s report on alcohol, drugs, and health (Chapter 4. Early Intervention, treatment and management of substance use disorders). Washington (DC): US Department of Health and Human ServicesGoogle Scholar
  127. O'Malley SS, Krishnan-Sarin S, Farren C, Sinha R, Kreek MJ (2002) Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary-adrenocortical axis. Psychopharmacology 160(1):19–29.  https://doi.org/10.1007/s002130100919 PubMedCrossRefGoogle Scholar
  128. Ooteman W, Koeter MW, Verheul R, Schippers GM, van den Brink W (2007) The effect of naltrexone and acamprosate on cue-induced craving, autonomic nervous system and neuroendocrine reactions to alcohol-related cues in alcoholics. Eur Neuropsychopharmacol 17(8):558–566.  https://doi.org/10.1016/j.euroneuro.2007.02.012 PubMedCrossRefGoogle Scholar
  129. Pang TY, Hannan AJ, Lawrence AJ (2018) Novel approaches to alcohol rehabilitation: modification of stress-responsive brain regions through environmental enrichment. Neuropharmacology.  https://doi.org/10.1016/j.neuropharm.2018.02.021
  130. Pani PP, Trogu E, Pacini M, Maremmani I (2014) Anticonvulsants for alcohol dependence. Cochrane Database Syst Rev 2:CD008544.  https://doi.org/10.1002/14651858.CD008544.pub2 CrossRefGoogle Scholar
  131. Pastor A, Jones DM, Currie J (2012) High-dose baclofen for treatment-resistant alcohol dependence. J Clin Psychopharmacol 32(2):266–268.  https://doi.org/10.1097/JCP.0b013e31824929b2 PubMedCrossRefGoogle Scholar
  132. Perry CJ (2016) Cognitive decline and recovery in alcohol abuse. J Mol Neurosci 60(3):383–389.  https://doi.org/10.1007/s12031-016-0798-4 PubMedCrossRefGoogle Scholar
  133. Perry CJ, Lawrence AJ (2017a) Addiction, cognitive decline and therapy: seeking ways to escape a vicious cycle. Genes Brain Behav 16(1):205–218.  https://doi.org/10.1111/gbb.12325 PubMedCrossRefGoogle Scholar
  134. Perry CJ, Lawrence AJ (2017b) Hurdles in basic science translation. Front Pharmacol 8:478.  https://doi.org/10.3389/fphar.2017.00478 PubMedPubMedCentralCrossRefGoogle Scholar
  135. Pignon B, Labreuche J, Auffret M, Gautier S, Deheul S, Simioni N, Cottencin O, Bordet R, Duhamel A Rolland B (2017) The dose-effect relationship of baclofen in alcohol dependence: a 1-year cohort study. Hum Psychopharmacol, 32(4). doi: https://doi.org/10.1002/hup.2593
  136. Project Match Research Group (1998) Matching alcoholism treatments to client heterogeneity: project MATCH three-year drinking outcomes. Alcohol Clin Exp Res 22(6):1300–1311CrossRefGoogle Scholar
  137. Randall PA, Jaramillo AA, Frisbee S, Besheer J (2015) The role of varenicline on alcohol-primed self-administration and seeking behavior in rats. Psychopharmacology 232(14):2443–2454.  https://doi.org/10.1007/s00213-015-3878-1 PubMedPubMedCentralCrossRefGoogle Scholar
  138. Ray LA, Hutchison KE (2004) A polymorphism of the mu-opioid receptor gene (OPRM1) and sensitivity to the effects of alcohol in humans. Alcohol Clin Exp Res 28(12):1789–1795PubMedCrossRefGoogle Scholar
  139. Ray LA, Hutchison KE (2007) Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study. Arch Gen Psychiatry 64(9):1069–1077.  https://doi.org/10.1001/archpsyc.64.9.1069 PubMedCrossRefGoogle Scholar
  140. Ray, L. A., Miranda, R. Jr., Mac Killop, J., McGeary, J., Tidey, J. W., Rohsenow, D. J., … Monti, P. M. (2009). A preliminary pharmacogenetic investigation of adverse events from topiramate in heavy drinkers. Exp Clin Psychopharmacol, 17(2), 122–129. doi: https://doi.org/10.1037/a0015700
  141. Reynaud M, Aubin HJ, Trinquet F, Zakine B, Dano C, Dematteis M, Trojak B, Paille F, Detilleux M (2017) A randomized, placebo-controlled study of high-dose baclofen in alcohol-dependent patients-the ALPADIR study. Alcohol Alcohol 52(4):439–446.  https://doi.org/10.1093/alcalc/agx030 PubMedCrossRefGoogle Scholar
  142. Rice SL, Hagler KJ, Tonigan JS (2014) Longitudinal trajectories of readiness to change: alcohol use and help-seeking behavior. J Stud Alcohol Drugs 75(3):486–495PubMedPubMedCentralCrossRefGoogle Scholar
  143. Riper H, Andersson G, Hunter SB, de Wit J, Berking M, Cuijpers P (2014) Treatment of comorbid alcohol use disorders and depression with cognitive-behavioural therapy and motivational interviewing: a meta-analysis. Addiction 109(3):394–406.  https://doi.org/10.1111/add.12441 PubMedPubMedCentralCrossRefGoogle Scholar
  144. Rosner S, Hackl-Herrwerth A, Leucht S, Lehert P, Vecchi S, Soyka M (2010a) Acamprosate for alcohol dependence. Cochrane Database Syst Rev 9:CD004332.  https://doi.org/10.1002/14651858.CD004332.pub2 CrossRefGoogle Scholar
  145. Rosner S, Hackl-Herrwerth A, Leucht S, Vecchi S, Srisurapanont M, Soyka M (2010b) Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev 12:CD001867.  https://doi.org/10.1002/14651858.CD001867.pub2 CrossRefGoogle Scholar
  146. Rossi S, Hallett M, Rossini PM, Pascual-Leone A, Safety of T. M. S. Consensus Group (2009) Safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and research. Clin Neurophysiol 120(12):2008–2039.  https://doi.org/10.1016/j.clinph.2009.08.016 PubMedPubMedCentralCrossRefGoogle Scholar
  147. Rubio G, Lopez-Munoz F, Ferre F, Martinez-Gras I, Ponce G, Pascual JM et al (2010) Effects of zonisamide in the treatment of alcohol dependence. Clin Neuropharmacol 33(5):250–253.  https://doi.org/10.1097/WNF.0b013e3181f0ed9a PubMedCrossRefGoogle Scholar
  148. Rupp CI, Kemmler G, Kurz M, Hinterhuber H, Fleischhacker WW (2012) Cognitive remediation therapy during treatment for alcohol dependence. J Stud Alcohol Drugs 73(4):625–634PubMedCrossRefGoogle Scholar
  149. Rupp CI, Derntl B, Osthaus F, Kemmler G, Fleischhacker WW (2017) Impact of social cognition on alcohol dependence treatment outcome: poorer facial emotion recognition predicts relapse/dropout. Alcohol Clin Exp Res 41(12):2197–2206.  https://doi.org/10.1111/acer.13522 PubMedCrossRefGoogle Scholar
  150. Sayegh CS, Huey SJ, Zara EJ, Jhaveri K (2017) Follow-up treatment effects of contingency management and motivational interviewing on substance use: a meta-analysis. Psychol Addict Behav 31(4):403–414.  https://doi.org/10.1037/adb0000277 PubMedCrossRefGoogle Scholar
  151. Schomerus G, Lucht M, Holzinger A, Matschinger H, Carta MG, Angermeyer MC (2011) The stigma of alcohol dependence compared with other mental disorders: a review of population studies. Alcohol Alcohol 46(2):105–112.  https://doi.org/10.1093/alcalc/agq089 PubMedCrossRefGoogle Scholar
  152. Skinner MD, Lahmek P, Pham H, Aubin HJ (2014) Disulfiram efficacy in the treatment of alcohol dependence: a meta-analysis. PLoS One 9(2):e87366.  https://doi.org/10.1371/journal.pone.0087366 PubMedPubMedCentralCrossRefGoogle Scholar
  153. Soyka M (2014) Nalmefene for the treatment of alcohol dependence: a current update. Int J Neuropsychopharmacol 17(4):675–684.  https://doi.org/10.1017/S1461145713001284 PubMedCrossRefGoogle Scholar
  154. Soyka M (2016) Nalmefene for the treatment of alcohol use disorders: recent data and clinical potential. Expert Opin Pharmacother 17(4):619–626.  https://doi.org/10.1517/14656566.2016.1146689 PubMedCrossRefGoogle Scholar
  155. Soyka M, Muller CA (2017) Pharmacotherapy of alcoholism—an update on approved and off-label medications. Expert Opin Pharmacother 18(12):1187–1199.  https://doi.org/10.1080/14656566.2017.1349098 PubMedCrossRefGoogle Scholar
  156. Steensland P, Simms JA, Holgate J, Richards JK, Bartlett SE (2007) Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking. Proc Natl Acad Sci U S A 104(30):12518–12523.  https://doi.org/10.1073/pnas.0705368104 PubMedPubMedCentralCrossRefGoogle Scholar
  157. Stoner SA, Arenella PB, Hendershot CS (2015) Randomized controlled trial of a mobile phone intervention for improving adherence to naltrexone for alcohol use disorders. PLoS One 10(4):e0124613.  https://doi.org/10.1371/journal.pone.0124613 PubMedPubMedCentralCrossRefGoogle Scholar
  158. Stormark KM, Laberg JC, Nordby H, Hugdahl K (1998) Heart rate responses indicate locked-in attention in alcoholics immediately prior to drinking. Addict Behav 23(2):251–255PubMedCrossRefGoogle Scholar
  159. Suchankova P, Yan J, Schwandt ML, Stangl BL, Jerlhag E, Engel JA, Hodgkinson CA, Ramchandani VA, Leggio L (2017) The Leu72Met polymorphism of the prepro-ghrelin gene is associated with alcohol consumption and subjective responses to alcohol: preliminary findings. Alcohol Alcohol 52(4):425–430.  https://doi.org/10.1093/alcalc/agx021 PubMedPubMedCentralCrossRefGoogle Scholar
  160. Suffoletto B, Kristan J, Callaway C, Kim KH, Chung T, Monti PM, Clark DB (2014) A text message alcohol intervention for young adult emergency department patients: a randomized clinical trial. Ann Emerg Med 64(6):664–672 e664.  https://doi.org/10.1016/j.annemergmed.2014.06.010 PubMedPubMedCentralCrossRefGoogle Scholar
  161. Suffoletto B, Kristan J, Chung T, Jeong K, Fabio A, Monti P, Clark DB (2015) An interactive text message intervention to reduce binge drinking in young adults: a randomized controlled trial with 9-month outcomes. PLoS One 10(11):e0142877.  https://doi.org/10.1371/journal.pone.0142877 PubMedPubMedCentralCrossRefGoogle Scholar
  162. Sundstrom C, Gajecki M, Johansson M, Blankers M, Sinadinovic K, Stenlund-Gens E, Berman AH (2016) Guided and unguided internet-based treatment for problematic alcohol use—a randomized controlled pilot trial. PLoS One 11(7):e0157817.  https://doi.org/10.1371/journal.pone.0157817 PubMedPubMedCentralCrossRefGoogle Scholar
  163. Tait RJ, Christensen H (2010) Internet-based interventions for young people with problematic substance use: a systematic review. Med J Aust 192(11 Suppl):S15–S21PubMedGoogle Scholar
  164. Tidey JW, Monti PM, Rohsenow DJ, Gwaltney CJ, Miranda R Jr, McGeary JE et al (2008) Moderators of naltrexone's effects on drinking, urge, and alcohol effects in non-treatment-seeking heavy drinkers in the natural environment. Alcohol Clin Exp Res 32(1):58–66.  https://doi.org/10.1111/j.1530-0277.2007.00545.x PubMedCrossRefGoogle Scholar
  165. Torrens M, Fonseca F, Mateu G, Farre M (2005) Efficacy of antidepressants in substance use disorders with and without comorbid depression. A systematic review and meta-analysis. Drug Alcohol Depend 78(1):1–22.  https://doi.org/10.1016/j.drugalcdep.2004.09.004 PubMedCrossRefGoogle Scholar
  166. Trim RS, Schuckit MA, Smith TL (2013) Predictors of initial and sustained remission from alcohol use disorders: findings from the 30-year follow-up of the San Diego Prospective Study. Alcohol Clin Exp Res 37(8):1424–1431.  https://doi.org/10.1111/acer.12107 PubMedPubMedCentralCrossRefGoogle Scholar
  167. Voges J, Muller U, Bogerts B, Munte T, Heinze HJ (2013) Deep brain stimulation surgery for alcohol addiction. World Neurosurg 80(3–4):S28 e21–31.  https://doi.org/10.1016/j.wneu.2012.07.011 PubMedCrossRefGoogle Scholar
  168. Walker DD, Roffman RA, Picciano JF, Stephens RS (2007) The check-up: in-person, computerized, and telephone adaptations of motivational enhancement treatment to elicit voluntary participation by the contemplator. Subst Abuse Treat Prev Policy 2:2.  https://doi.org/10.1186/1747-597X-2-2 PubMedPubMedCentralCrossRefGoogle Scholar
  169. Walter M, Gerhard U, Gerlach M, Weijers HG, Boening J, Wiesbeck GA (2006) Cortisol concentrations, stress-coping styles after withdrawal and long-term abstinence in alcohol dependence. Addict Biol 11(2):157–162.  https://doi.org/10.1111/j.1369-1600.2006.00018.x PubMedCrossRefGoogle Scholar
  170. Warden A, Erickson E, Robinson G, Harris RA, Mayfield RD (2016) The neuroimmune transcriptome and alcohol dependence: potential for targeted therapies. Pharmacogenomics 17(18):2081–2096.  https://doi.org/10.2217/pgs-2016-0062 PubMedPubMedCentralCrossRefGoogle Scholar
  171. White A, Kavanagh D, Stallman H, Klein B, Kay-Lambkin F, Proudfoot J et al (2010) Online alcohol interventions: a systematic review. J Med Internet Res 12(5):e62.  https://doi.org/10.2196/jmir.1479 PubMedPubMedCentralCrossRefGoogle Scholar
  172. WHO (2014). Global status report on alcohol and healthGoogle Scholar
  173. Wright J (1978) Endocrine effects of alcohol. Clin Endocrinol Metab 7(2):351–367PubMedCrossRefGoogle Scholar
  174. You CW, Chen YC, Chen CH, Lee CH, Kuo PH, Huang MC, Chu HH (2017) Smartphone-based support system (SoberDiary) coupled with a Bluetooth breathalyser for treatment-seeking alcohol-dependent patients. Addict Behav 65:174–178.  https://doi.org/10.1016/j.addbeh.2016.10.017 PubMedCrossRefGoogle Scholar
  175. Zilverstand A, Parvaz MA, Moeller SJ, Goldstein RZ (2016) Cognitive interventions for addiction medicine: understanding the underlying neurobiological mechanisms. Prog Brain Res 224:285–304.  https://doi.org/10.1016/bs.pbr.2015.07.019 PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Erin J. Campbell
    • 1
    • 2
  • Andrew J. Lawrence
    • 1
    • 2
  • Christina J. Perry
    • 1
    • 2
  1. 1.The Florey Institute of Neuroscience and Mental Health, Melbourne Brain CentreParkvilleAustralia
  2. 2.Florey Department of Neuroscience and Mental HealthThe University of MelbourneParkvilleAustralia

Personalised recommendations